In people with MASLD but without diabetes, liver fat production goes down while they are losing weight through medication or lifestyle changes, but rises again after they stop the treatment.
Mechanism
Synthesis from 1 study
When a person takes a drug that helps the body use sugar better, the liver makes less new fat. When they stop taking it, sugar control gets worse, and the liver starts making more fat again. Other changes like inflammation or gut bacteria shifts might help, but the main reason is the return of high...
Most probable mechanism
When a person takes a drug that mimics a gut hormone, it helps the body use sugar more efficiently by making the pancreas release more insulin only when blood sugar is high and helping fat tissue soak up extra sugar. This reduces the amount of sugar available for the liver to turn into new fat. When the drug is stopped, the body’s ability to handle sugar gets worse, sugar builds up in the blood, and the liver starts making more fat again.
Activation of GLP-1 receptors on pancreatic beta cells enhances glucose-dependent insulin secretion.
Increased insulin sensitivity in subcutaneous adipose tissue improves systemic glucose clearance, reducing circulating glucose levels.
Lower circulating glucose availability reduces substrate flux into the hepatic de novo lipogenesis pathway.
Cessation of GLP-1 receptor signaling leads to impaired glucose homeostasis and elevated systemic glucose levels.
Elevated glucose availability reactivates hepatic de novo lipogenesis, increasing hepatic triglyceride synthesis.
Less supported by current evidence, but not ruled out
When the drug is stopped, fat tissue releases inflammatory signals that may signal the liver to produce more fat, even if sugar levels aren't drastically higher.
Abrupt termination of GLP-1 receptor signaling alters gene expression in subcutaneous adipose tissue.
Dysregulated adipose tissue increases secretion of proinflammatory cytokines into circulation.
Circulating inflammatory mediators may directly stimulate hepatic lipogenic enzyme activity.
After stopping the drug, the gut bacteria change in a way that may help the body pull more energy from food, which could lead the liver to make more fat.
Cessation of GLP-1 receptor signaling shifts gut microbial composition toward increased Firmicutes and decreased Bacteroidetes.
Altered microbial profile enhances energy extraction from dietary carbohydrates.
Increased energy harvest elevates hepatic substrate availability for de novo lipogenesis.
Evidence from Studies
Supporting (0)
Community contributions welcome
Contradicting (1)
Community contributions welcome
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.